Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health (P30DK072482, R35HL135816, U54TR001368)

This publication has 25 references indexed in Scilit: